Comparative effectiveness of dexamethasone in treatment of hospitalized COVID-19 patients in the United States during the first year of the pandemic: Findings from the National COVID Cohort Collaborative (N3C) data repository.

Richard ZhouKaitlyn E JohnsonJustin F Rousseau Paul J Rathouznull null

Published in: PloS one (2024)

We add evidence that dexamethasone provides benefit with respect to mortality and severe outcomes in a diverse, national hospitalized sample, prior to vaccine availability.

Keyphrases

sars cov
coronavirus disease
quality improvement
high dose
low dose
respiratory syndrome coronavirus
electronic health record
risk factors
early onset
type diabetes
metabolic syndrome
coronary artery disease
skeletal muscle
weight loss